Cyclotides and HIV: Plant Peptides That Attack Viral Membranes

Peptide-Based HIV Vaccines

100+ cyclotides identified

Over 100 cyclotides have been isolated from plant families, with several showing potent anti-HIV activity by disrupting viral lipid membranes.

Ireland et al., Biopolymers, 2008

Ireland et al., Biopolymers, 2008

View as image

Most peptides degrade within minutes in biological environments. Cyclotides do not. These plant-derived macrocyclic peptides, approximately 30 amino acids in length, possess a head-to-tail cyclized backbone reinforced by three interlocking disulfide bonds that form a structure called the cyclic cystine knot. This architecture provides exceptional resistance to thermal, chemical, and enzymatic degradation.^[1] Among the peptide-based approaches to HIV, cyclotides represent a distinct strategy: rather than targeting viral proteins or training the immune system, they attack the lipid envelope that surrounds the virus itself.

Gustafson, McKee, and Bokesch (2004) reported that cyclotides inhibit HIV through a mechanism that involves disrupting the viral membrane, and Ireland et al. (2008) confirmed that this activity correlates with the hydrophobicity of specific loop regions on the cyclotide surface.^[2][3]

What Makes Cyclotides Structurally Unique

Cyclotides were first defined as a peptide family by Craik et al. (1999), who identified 16 novel macrocyclic peptides from Viola hederaceae, Viola odorata, and Oldenlandia affinis. The defining features are a head-to-tail cyclized peptide backbone (no free N- or C-terminus) and a cystine knot formed by three disulfide bonds, where two disulfides and their connecting backbone segments form an embedded ring that is threaded by the third disulfide bond.^[1]

This cyclic cystine knot topology has no equivalent in other peptide families. It creates a compact, globular structure that resists boiling, extreme pH, and proteolytic enzymes. The practical consequence is that cyclotides survive conditions that destroy most peptides, making them candidates for oral drug delivery, a persistent challenge in peptide therapeutics.

Cyclotides are classified into two subfamilies based on the presence or absence of a cis-Pro peptide bond in loop 5: the Mobius subfamily (containing the twist, including kalata B1) and the bracelet subfamily (without it). Both subfamilies have members with anti-HIV activity.^[4]

How Cyclotides Inhibit HIV

Membrane Disruption, Not Receptor Binding

The anti-HIV mechanism of cyclotides is fundamentally different from conventional antiretroviral drugs and from fusion inhibitor peptides like enfuvirtide. Rather than binding to a specific viral or host protein, cyclotides target the lipid bilayer that forms the HIV envelope.

Sando et al. (2011) demonstrated this conclusively by synthesizing a mirror-image (D-amino acid) version of kalata B1. If the cyclotide's activity depended on binding to a chiral protein receptor, the mirror image would be inactive because its shape would not match the receptor's binding site. Instead, the D-kalata B1 retained full biological activity, proving that cyclotide function depends on interactions with lipid membranes rather than protein receptors.^[5]

This has important implications. Protein-targeting drugs are susceptible to resistance mutations that alter the target protein's shape. A membrane-disrupting agent faces a much higher barrier to resistance because the virus would need to alter its fundamental lipid composition, not just mutate a single protein.

The Role of Phosphatidylethanolamine

Henriques et al. (2011) identified the specific lipid interactions driving anti-HIV activity. Kalata B1 requires phosphatidylethanolamine (PE) phospholipids to interact with membranes. HIV particles bud from host cell lipid rafts that are enriched in PE, making their envelopes particularly susceptible to cyclotide binding.^[6]

The study showed that biological activity depends on peptide oligomerization at the membrane surface: individual cyclotide molecules bind to PE-containing membranes and then cluster together, creating localized membrane disruption. The affinity for membranes is modulated by both specific PE headgroup recognition and nonspecific hydrophobic interactions with the lipid tails. This dual requirement explains why cyclotides preferentially disrupt certain membrane types over others.^[6]

Why the Circular Backbone Is Essential

Daly, Gustafson, and Craik (2004) tested whether the cyclic backbone was necessary for anti-HIV activity by creating acyclic permutants of kalata B1, linear versions opened at different points in the backbone. None of the linear variants displayed anti-HIV activity. This demonstrates that the circular backbone is not merely a stability feature; it is functionally required for the membrane-disrupting activity that drives HIV inhibition.^[4]

The bracelet subfamily of cyclotides had previously been shown to have anti-HIV activity, but this study extended the finding to the Mobius subfamily member kalata B1, demonstrating that anti-HIV activity is a broader property of the cyclotide family despite extensive sequence differences between the subfamilies.^[4]

The Anti-HIV Cyclotide Landscape

Gustafson, McKee, and Bokesch (2004) provided the first comprehensive review of anti-HIV cyclotides. Circulin A and circulin B, isolated from the tropical tree Chassalia parvifolia, were among the first cyclotides identified with anti-HIV activity. Kalata B1 and several variants from Oldenlandia affinis also showed inhibitory activity. Additional anti-HIV cyclotides were subsequently identified from Viola species and other Violaceae plants.^[2]

Ireland et al. (2008) expanded the picture, noting that over 100 cyclotides had been reported by that time from two phylogenetically distant plant families, the Rubiaceae and Violaceae. Within cyclotide subfamilies, there is a correlation between the hydrophobicity of certain loop regions and HIV inhibition. Charged residues in these loops also impact activity, presumably by modulating membrane binding.^[3]

Not all cyclotides are equally potent against HIV. The structure-activity relationship studies suggest that the balance of hydrophobic and charged residues on the cyclotide surface determines how strongly it binds to PE-enriched membranes and how effectively it disrupts them. This provides a framework for engineering more potent anti-HIV cyclotides, though the effort remains preclinical.

Natural Function: Plant Defense

The anti-HIV activity of cyclotides is a pharmacological observation, not their evolved purpose. In nature, cyclotides serve as plant defense molecules.

Craik (2012) reviewed the host-defense activities of cyclotides, noting that their primary natural role is protecting plants from insect pests. Cyclotides disrupt the gut membranes of insect larvae, causing growth inhibition and mortality. This insecticidal activity operates through the same membrane-disruption mechanism that drives anti-HIV effects: targeting PE-containing lipid bilayers.^[7]

The broader context of cyclotide biology includes antimicrobial, hemolytic, and cytotoxic activities, all linked to membrane interactions. The anti-HIV activity is a specific instance of a general capacity to disrupt biological membranes containing certain phospholipid compositions.

Cyclotides as Drug Scaffolds

Beyond their direct biological activities, cyclotides have attracted attention as molecular scaffolds for drug design. Their exceptional stability means that bioactive sequences grafted onto the cyclotide framework retain activity even in harsh physiological environments.

Craik, Swedberg, Mylne, and Cemazar (2012) reviewed the use of cyclotides as drug design templates. The cyclic cystine knot provides a stable backbone into which foreign peptide sequences can be inserted, creating chimeric molecules with novel activities delivered on a protease-resistant chassis. The approach has been tested for pain, cancer, and cardiovascular targets.^[8]

Craik, Mylne, and Daly (2010) noted that cyclotide scaffolds could address one of the major limitations of peptide drugs: oral bioavailability. Because cyclotides survive gastric conditions, they offer a rare opportunity to create orally active peptide therapeutics.^[9]

Hyun (2025) published the most recent assessment of cyclotides as scaffolds for oral peptide therapeutics. The review highlighted that cyclotides possess intrinsic cell-penetrating capacities in addition to their stability, allowing them to cross epithelial barriers and reach intracellular targets. These properties position cyclotides as ideal templates for the design of novel peptide therapeutics that can be taken by mouth rather than injected.^[10]

Limitations of Cyclotide Anti-HIV Research

The anti-HIV evidence for cyclotides is entirely preclinical, limited to in vitro assays. Several factors limit translational progress:

Selectivity. Cyclotides disrupt membranes based on lipid composition, not viral identity. This means they can also damage host cell membranes. The hemolytic activity of some cyclotides (lysis of red blood cells) illustrates this selectivity problem. Henriques et al. (2011) showed that PE content determines susceptibility, and HIV membranes are PE-enriched, but healthy human cells also contain PE.^[6] Achieving therapeutic concentrations that disrupt viral particles without unacceptable host cell damage remains unresolved.

Potency. The anti-HIV concentrations reported for most cyclotides are in the micromolar range, substantially higher than the nanomolar concentrations achieved by approved antiretroviral drugs. Cyclotides would need significant potency improvements to be competitive with existing HIV treatments.

Mechanism of action limitations. Membrane disruption prevents viral entry and destroys free viral particles, but it does not target integrated proviral DNA or the viral replication machinery inside already-infected cells. Cyclotides would not be effective against the latent viral reservoir, the central obstacle to HIV cure research.

Manufacturing. Cyclotides contain three disulfide bonds that must form correctly for proper folding. Chemical synthesis is possible but remains costly at scale. Recombinant production faces challenges with disulfide bond formation and backbone cyclization.

In vivo pharmacology. While cyclotides are stable in gastric conditions, their biodistribution, pharmacokinetics, and in vivo anti-HIV efficacy have not been established. No cyclotide has entered clinical trials for any antiviral indication.

Where Cyclotide HIV Research Stands

The evidence establishes that cyclotides inhibit HIV in vitro through a membrane-disruption mechanism that is mechanistically distinct from all approved antiretroviral drugs. The structure-activity relationships are well characterized: the cyclic backbone is essential, PE interactions drive selectivity, and hydrophobic loop regions modulate potency.

The therapeutic application of cyclotides against HIV remains speculative. The selectivity and potency barriers are substantial, and the existing antiretroviral arsenal is highly effective. The more likely pharmaceutical path for cyclotides may be as drug scaffolds, using their stability and cell-penetrating properties to deliver other therapeutic payloads, rather than as direct antiviral agents. Understanding how peptides block HIV entry through fusion inhibition represents a more clinically advanced approach to peptide-based HIV therapy, with enfuvirtide already approved.

The cyclotide story illustrates a recurring theme in peptide research: natural products with fascinating biological activities that expand scientific understanding but face steep translational hurdles. Whether cyclotides find their clinical niche in HIV or elsewhere, their structural innovations, particularly the cyclic cystine knot, continue to influence peptide drug design across multiple therapeutic areas.

The Bottom Line

Cyclotides are ultra-stable cyclic plant peptides that inhibit HIV by disrupting the viral lipid envelope through interactions with phosphatidylethanolamine phospholipids. The cyclic backbone is essential for activity, and the mechanism is receptor-independent, operating through membrane disruption rather than protein binding. Over 100 cyclotides have been identified with varying anti-HIV potency, but all evidence remains in vitro. Selectivity, potency, and manufacturing challenges limit therapeutic prospects, though cyclotides show promise as stable scaffolds for oral peptide drug design.

Frequently Asked Questions

What are cyclotides and where do they come from?

Cyclotides are macrocyclic peptides of approximately 30 amino acids found in plants, primarily in the Rubiaceae (coffee family) and Violaceae (violet family). They have a unique structure: a head-to-tail cyclized backbone combined with three interlocking disulfide bonds forming a cyclic cystine knot. This structure makes them exceptionally resistant to heat, acid, and enzymatic degradation. Over 100 different cyclotides have been identified, with their natural function believed to be protecting plants from insect pests (Craik et al., 1999).

How do cyclotides kill HIV?

Cyclotides inhibit HIV by disrupting the lipid membrane that forms the viral envelope, not by binding to a viral protein. They interact specifically with phosphatidylethanolamine (PE) phospholipids, which are enriched in HIV's membrane. Individual cyclotide molecules bind to PE-containing membranes and then cluster together, creating localized membrane disruption that prevents the virus from infecting cells. A mirror-image version of the cyclotide kalata B1 retained full anti-HIV activity, confirming this mechanism is receptor-independent (Henriques et al., 2011; Sando et al., 2011).

Can cyclotides be used to treat HIV in people?

No cyclotide has been tested in humans for HIV treatment. All anti-HIV evidence comes from laboratory cell culture assays. Several obstacles limit clinical translation: cyclotides can also damage host cell membranes (selectivity problem), their anti-HIV concentrations are in the micromolar range compared to nanomolar potency of approved antiretrovirals, and they cannot target the latent HIV reservoir inside already-infected cells. Cyclotides may find greater pharmaceutical utility as drug scaffolds rather than direct antiviral agents.

Why is the circular backbone important for anti-HIV activity?

When researchers created linear (open-ended) versions of the cyclotide kalata B1 by breaking the circular backbone at different positions, every linear variant lost all anti-HIV activity. This demonstrates that the cyclic backbone is not just a stability feature but is functionally required for the membrane-disrupting activity that kills HIV. The circular structure likely determines how the peptide inserts into and disrupts lipid bilayers (Daly et al., 2004).

Could cyclotides become oral drugs?

Cyclotides are among the most promising candidates for oral peptide therapeutics because they survive gastric acid and digestive enzymes that destroy most peptides. They also have intrinsic cell-penetrating properties that allow them to cross epithelial barriers. Researchers are using cyclotides as stable scaffolds onto which therapeutic sequences can be grafted, creating chimeric peptides that retain oral bioavailability. This approach is being explored for pain, cancer, and cardiovascular targets, though no cyclotide-based oral drug has reached clinical trials (Hyun, 2025).

How are cyclotides different from other anti-HIV peptides?

Most peptide-based HIV therapies, like the approved drug enfuvirtide, work by binding to specific viral proteins to block viral entry. Cyclotides take a completely different approach: they attack the lipid membrane surrounding the virus rather than any protein target. This membrane-based mechanism is harder for the virus to develop resistance against because it would require changing the fundamental lipid composition of the viral envelope. However, cyclotides are less potent and less selective than protein-targeting peptides, which is why enfuvirtide reached clinical use while cyclotides have not.